Luseogliflozin: SGLT2 inhibitor treatment of diabetes

Drugs of the Future

Volumn 37, Issue 9, 2012, Pages 637-643

  Tiwari, A ^a  

^a Advinus Therapeutics Private Limited Bangalore   (India)

Author keywords

Diabetes; Luseogliflozin; SGLT2 inhibitor; TS 071

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LUSEOGLIFLOZIN; TRIACYLGLYCEROL;

COMPETITIVE INHIBITION; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STABILITY; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; IC 50; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; POLLAKISURIA; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84952986810     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2012.037.09.1848191     Document Type: Review

References (32)

1. Kakinuma, H., Oi, T., Hashimoto-Tsuchiya, Y. et al. (1S)-1,5-Anhydro-1- [5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 2010, 53(8): 3247-61.
2. Kakinuma, H., Hashimoto, Y., Oi, T., Hirano, H. (Taisho Pharmaceutical Co., Ltd.). 1-Thio-D-glucitol derivatives. EP 1845095, JP 2010059173, US 2008132563, US 7910619, US 2011098469, US 8017792, WO 2006073197.
3. American Diabetes Association. Postprandial blood glucose. Diabetes Care 2001, 24(4): 775-8.
4. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004, 27(Suppl. 1): S15-35.
5. Muller, W.A., Faloona, G.R., Aguilar-Parada, E., Unger, R.H. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970, 283(3): 109-15.
6. Reaven, G.M., Chen, Y.D., Golay, A., Swislocki, A.L., Jaspan, J.B. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes-mellitus. J Clin Endocrinol Metab 1987, 64(1): 106-10. (Pubitemid 17015886)
7. Unger, R.H., Orci, L. Glucagon and the A cell: Physiology and pathophysiology (second of two parts). N Engl J Med 1981, 304(26): 1575-80. (Pubitemid 11122505)
8. Unger, R.H., Orci, L. Glucagon and the A cell: Physiology and pathophysiology (first of two parts). N Engl J Med 1981, 304(25): 1518-24. (Pubitemid 11065936)
9. Nathan, D.M., Buse, J.B., Davidson, M.B., Ferrannini, E., Holman, R.R., Sherwin, R., Zinman, B. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32(1): 193-203.
10. Nathan, D.M., Buse, J.B., Davidson, M.B., Heine, R.J., Holman, R.R., Sherwin, R., Zinman, B. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy - A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006, 29(8): 1963-72. (Pubitemid 44156663)
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131): 837-53.
12. Saydah, S.H., Fradkin, J., Cowie, C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004, 291(3): 335-42. (Pubitemid 38101606)
13. Harris, M.I. Racial and ethnic differences in health insurance coverage for adults with diabetes. Diabetes Care 1999, 22(10): 1679-82. (Pubitemid 29458392)
14. Koro, C.E., Boialin, S.J., Bourgeois, N., Fedder, D.O. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: A preliminary report. Diabetes Care 2004, 27(1): 17-20. (Pubitemid 38196703)
15. Kanai, Y., Lee, W.S., You, G., Brown, D., Hediger, M.A. The human kidney low affinity Na+/glucose cotransporter SGLT2, Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994, 93(1): 397-404.
16. Hediger, M.A., Rhoads, D.B. Molecular physiology of sodium-glucose cotransporters. Physiol Rev 1994, 74(4): 993-1026. (Pubitemid 24328943)
17. Vallon, V., Platt, K.A., Cunard, R. et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011, 22(1): 104-12.
18. Magen, D., Sprecher, E., Zelikovic, I., Skorecki, K. A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria. Kidney Int 2005, 67(1): 34-41. (Pubitemid 40019223)
19. Kleta, R., Stuart, C., Gill, F.A., Gahl, W.A. Renal glucosuria due to SGLT2 mutations. Mol Genet Metab 2004, 82(1): 56-8. (Pubitemid 38521129)
20. Santer, R., Kinner, M., Lassen, C.L. et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003, 14(11): 2873-82. (Pubitemid 37305650)
21. Wright, E.M., Turk, E., Martin, M.G. Molecular basis for glucose-galactose malabsorption. Cell Biochem Biophys 2002, 36(2-3): 115-21. (Pubitemid 41270716)
22. Wright, E.M. Renal Na+-glucose cotransporters. Am J Physiol Renal Physiol 2001, 280(1): F10-8.
23. Anderson, S.L., Marrs, J.C. Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacother 2012, 46(4): 590-8.
24. Ferrannini, E., Solini, A. SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects. Nat Rev Endocrinol 2012, 8(8): 495-502.
25. Yamamoto, K., Uchida, S., Kitano, K. et al. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with antihyperglycaemic activity. Br J Pharmacol 2011, 164(1): 181-91.
26. st Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 24-28, San Diego) 2011, Abst 0983-P.
27. th Annu Meet Eur Assoc Study Diabetes (EASD) (Sept 12-16, Lisbon) 2011, Abst 845.
28. st Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 24-28, San Diego) 2011, Abst 1000-P.
29. st Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 24-28, San Diego) 2011, Abst 1140-P.
30. th Annu Meet Eur Assoc Study Diabetes (EASD) (Sept 12-16, Lisbon) 2011, Abst 846.
31. st Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 24-28, San Diego) 2011, Abst 0998-P.
32. th Annu Meet Eur Assoc Study Diabetes (EASD) (Sept 12-16, Liston) 2011, Abst OP25-148.